Month: June 2025

Introduction and Objective: Fasting during Ramadan puts people with type 1 diabetes (PWT1D) at risk of dysglycemia and diabetic ketoacidosis (DKA). Recent studies have shown the clinical effectiveness of automated insulin delivery (AID) systems in PWT1D who fast during Ramadan. Here, we compare the effectiveness and safety profiles of the Medtronic 780G versus Tandem Control-IQ […]

Introduction and Objective: Most people with type 1 diabetes (PWT1D) are advised to not fast during Ramadan because of dysglycemia risks. We compared efficacy, safety profiles, and fear of hypoglycemia (FH) during Ramadan fasting in users of 4 insulin delivery modalities.Methods: Four treatment groups were compared: automated insulin delivery (AID) (n=114), sensor augmented pump (SAP) […]

Introduction and Objective: Glycemic control in diabetes can differ from person to person and automated insulin delivery (AID) with frequent autocorrections provides more personalized diabetes management. The present study assessed glycemic outcomes and insulin use of MiniMed™ 780G system (MM780G) users with different daily carbohydrate intake.Methods: CareLink™ personal data (as of October 26, 2024) of […]

Introduction and Objective: Management of dysglycemia in older adults with insulin-requiring diabetes can be challenging and automated insulin delivery is reported to improve glycemic outcomes in this population.1,2 The present study evaluated MiniMedTM 780G system (MM780G) performance in a real-world US population aged ≥65 years.Methods: CareLink™ data (up to December 18, 2024) of consenting US […]

Introduction and Objective: Type 2 diabetes (T2D) and obesity are associated with left ventricular (LV) dysfunction, but the impact of exercise interventions on LV function remains unclear. This study aims to assess LV function in individuals with obesity, with and without T2D via supervised aerobic exercise training, using cardiac MRI and time-resolved three-dimensional phase-contrast MRI […]

Introduction and Objective: Systemic inflammation promotes insulin resistance (IR) and comorbidities like type 2 diabetes. Multiple CD4+ T cell subsets support inflammation in people with excess weight or obesity (herein, obesity). Autophagy is one key mechanism that regulates T cell-generated cytokines and thus inflammation. We tested the hypothesis that obesity-associated changes in T cell autophagy […]

Introduction and Objective: Metabolic dysfunction-associated steatohepatitis (MASH) is a leading cause of cirrhosis. NIS2+™is a novel blood-based diagnostic test developed to identify “at-risk” MASH (steatohepatitis with significant fibrosis stage ≥F2) that combines miR-34a-5p (microRNA linked to altered lipid metabolism) and YKL-40 (biomarker of fibrosis). Our aim was to assess the prevalence of “at-risk” MASH by […]

Introduction and Objective: There is a gap in understanding diabetes technology use among older people with type 1 and type 2 diabetes (pwt1d, pwt2d). A survey in Germany, Austria and Switzerland investigated the association between age and diabetes technology use.Methods: Between 2023/11 and 2024/01, pwd and parents of children with diabetes reported their use of […]

Introduction and Objective: Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are closely associated with an increased risk of congestive heart failure (CHF). This study aimed to evaluate the long-term incidence of CHF in patients with NAFLD according to glycemic status, using a nationwide cohort of Korean adults.Methods: This longitudinal cohort study […]

Introduction and Objective: AZD6234, a long-acting amylin analog in clinical development for weight management, reduces body weight (BW) in diet-induced obese (DIO) rats without a loss of lean mass. Semaglutide, a GLP-1R agonist, reduces BW with both fat mass and lean mass loss. Here, we aim to understand the impact of combined treatment of AZD6234 […]